Can artificial intelligence function as a partner in scientific discovery, capable of generating novel, testable hypotheses ...
ROCKVILLE, Md., Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of ...
Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced the publication online of Part 1 results from ...
Fig 1. Mechanistic insights into kynurenine pathway modulation in renal cell carcinoma and therapeutic implications. This schematic illustrates the interplay between the kynurenine pathway, chromatin ...
MedPage Today on MSN
Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy
Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 years and older. Pathologic upregulation of HDAC occurs in DMD, leading to ...
ABT-301, an HDAC1/2/3 inhibitor, enhances immune response and tumor microenvironment, potentially improving immune checkpoint inhibitor efficacy in metastatic colorectal cancer. The phase 1/2 trial ...
Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...
High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases. Nautilus, a phase 1b/2 trial of combining oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback